This is a working overview of research chemical, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-29. Anything still debated is marked as such rather than presented as settled.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
== Nomenclature == Thiols are sometimes referred to as mercaptans () or mercapto compounds, a term introduced in 1832 by William Christopher Zeise and is derived from the Latin mercurio captāns ('capturing mercury') because the thiolate group (RS−) bonds very strongly with mercury compounds. There are several ways to name the alkylthiols:
== Covalently modulated enzymes == Here, the active and inactive form of the enzymes are altered due to covalent modification of their structures which is catalysed by other enzymes. This type of regulation consists of the addition or elimination of some molecules which can be attached to the enzyme protein. The most important groups that work as modifiers are phosphate, methyl, uridine, adenine and adenosine diphosphate ribosyl. These groups are joined to or eliminated from the protein by other enzymes. The most remarkable covalent modification is phosphorylation. Serine, Threonine and Tyrosine are common amino acids that participate in covalent modifications and are used to control enzyme’s catalytic activities. Kinase and phosphatases are commonly known enzymes that affect these modifications, which result in shifting of conformational states of the binding affinity to substrate.
From 1969 to 1971, Sanders resided in Montpelier. After moving to Burlington, he began his electoral political career as a member of the Liberty Union Party, a national umbrella party for various socialist-oriented state parties, originating in the anti-war movement and the People's Party. He ran as the Liberty Union candidate for governor of Vermont in 1972 and 1976 and as a candidate in the special election for U.S. senator in 1972 and in the general election in 1974. In the 1974 senatorial race, he finished third (5,901 votes; 4%), behind 34-year-old Chittenden County state's attorney Patrick Leahy (D; 70,629 votes; 49%) and two-term incumbent U.S. Representative Dick Mallary (R; 66,223 votes; 46%). In 1971, while researching an article for Liberty Union's newspaper Movement, Sanders stayed at Myrtle Hill Farm, a Vermont back to the land commune. He was asked to leave after three days for failing to contribute physical labor expected of all members. Some residents complained that Sanders spent his time engaging others in political discussions, distracting them from their work, with one member claiming the only way "any work was going to get accomplished" was if people were pulled out of Sanders's orbit. The 1976 campaign was the zenith of the Liberty Union's influence, with Sanders collecting 11,317 votes for governor and the party.
After the unbound probes are washed away, the Western blot is ready for detection of the probes that are labeled and bound to the protein of interest. In practical terms, not all Westerns reveal protein only at one band in a membrane. Size approximations are taken by comparing the stained bands to that of the marker or ladder loaded during electrophoresis. The process is commonly repeated for a structural protein, such as actin or tubulin, that should not change between samples. The amount of target protein is normalized to the structural protein to control between groups. A superior strategy is the normalization to the total protein visualized with trichloroethanol or epicocconone. This practice ensures correction for the amount of total protein on the membrane in case of errors or incomplete transfers. (see Western blot normalization)
Sources: en.wikipedia.org
=== TruD === TruD is able to modify a variety of RNA, and it is unclear how these different RNA substrates are recognized. PUS 7 modifies U2 snRNA at the position 35 and this modification will increase when the cells are in heat shock. Another modification is cytoplasmic tRNA in position 13, and position 35 in pre-tRNATyr. PUS 7 modifies almost specificity does not depend on the type of RNA as mRNA show pseudouridylated by PUS 7. Recognize this the sequence of the RNA, UGUAR with the second U being the nucleotide that will be modified. The pseudouridylation of mRNA by PUS 7 increases during heat shock, because the protein moves from the nucleus to the cytoplasm. The modification is thought to increase the stability of mRNA during heat shock before the RNA goes to the nucleus or mitochondria, but more studies are needed.
However, this difference is usually neglected most of the time (that is whenever we are not dealing with processes such as sound absorption and attenuation of shock waves, where second viscosity coefficient becomes important) by explicitly assuming
==== Site selection ==== To prepare for branding a site on the animal's hide must be selected. Careful selection is important for two reasons: first, certain states and counties have various laws regarding legal brand placement and second, the arrangement of muscles beneath the skin determines whether the death of pigment cells occurs evenly. If a brand is attempted in an area that is partly muscle and partly bone the harder bone will take most of the brand while the flexible muscle tissue is less efficiently cooled and so more lightly branded. Modern branding operations are often recorded on video to facilitate the production of records at a later date.
On March 13, 2019, three years after voters narrowly rejected its repeal in the 2016 California Proposition 62, Newsom declared a moratorium on the state's death penalty, preventing any execution in the state as long as he remained governor. The move also led to the withdrawal of the state's current lethal injection protocol and the execution chamber's closure at San Quentin State Prison. In a CBS This Morning interview, Newsom said that the death penalty is "a racist system ... that is perpetuating inequality. It's a system that I cannot in good conscience support." The moratorium granted a temporary reprieve for all 737 inmates on California's death row, then the largest death row in the Western Hemisphere. In January 2022, Newsom directed the state to begin dismantling its death row in San Quentin, to be transformed into a "space for rehabilitation programs", as all the condemned inmates were moving to other prisons that have maximum security facilities. The state's voters upheld capital punishment in 2012 and 2016, agreeing when they did so in 2016 to move the condemned to other prisons. While a 2021 poll by the UC Berkeley Institute of Governmental Studies and co-sponsored by the Los Angeles Times suggested declining support for capital punishment among California's voters, Republican opponents criticized Newsom's moves to halt capital punishment in California as defiance of the will of voters, and capital punishment advocates said they denied closure to murder victims' families.
Instead, they added in some of the basics of survival gameplay: instead of potentially killing the player character, factors like nourishment and rest will buff the character if satisfied or debuff them if not met, and the permadeath facet was taken out, made as an option for more hard-core players. Some issues arose from Compulsion's onboarding of new staff as the game grew. While the experience these new developers brought to the game ultimate improved it according to Provost, their initial contributions shifted the direction of the game and created instability in the development process. In retrospective, Provost stated that they likely would have dropped the procedurally generated elements once they had focused more on the narrative, as the combination of the two "doesn't make any sense". Compulsion also put more effort into creating narrative encounters with unique characters, and level spaces for these to occur within the procedurally generated world. Feedback from players were positive about the unique characters they had made to support the shorter form of the game, so Compulsion had to spend more time in creating backgrounds and stories for more unique characters, which took away from some other story aspects they wanted to tell. They also had little time to make new cinematics to help explain some of these backstories, and instead resorted to using audio recordings to help flesh out the characters.
Sources: en.wikipedia.org
=== Incidence === Beta thalassemia is most prevalent in the "thalassemia belt" which includes areas in Sub-Saharan Africa, and the Mediterranean extending into the Middle East and Southeast Asia. This geographical distribution is thought to be due to the beta-thalassemia carrier state (beta-thalassemia minor) conferring resistance to malaria. In 2005, it was estimated that 1.5% of the world's population are carriers and 60,000 affected infants are born with the thalassemia major annually.
amplicon Any DNA or RNA sequence or fragment that is the source and/or product of an amplification reaction. The term is most frequently used to describe the numerous copied fragments that are the products of the polymerase chain reaction or ligase chain reaction, though it may also refer to sequences that are amplified naturally within a genome, e.g. by gene duplication.
On 8 June 1936, the Matignon Accords granted the 40 hours workweek to the workers, as well as right of collective bargaining, right of strike action, and dismantled all laws preventing organization of trade-unions. Elsewhere, democratic socialists remained hostile to Stalinism and rejected the popular front strategy. For example, the Communist Party leader Earl Russell Browder offered to be Thomas' running mate on a joint Socialist Party–Communist Party ticket, but Thomas rejected this overture. After the election of a Popular Front government in Spain in 1936 a fascist military revolt led to the Spanish Civil War. Democratic socialists from around the world fought on the side of the Republican government, for instance in the ILP Contingent of the International Brigades, in which George Orwell served. The crisis in Spain also brought down Blum's Popular Front government in France and ultimately the Popular Fronts were not able to prevent the spread of fascism or the aggressive plans of the fascist powers.
== Quality, efficiency, and access == Evidence-based medicine, prevention of medical error (and other "iatrogenesis"), and avoidance of unnecessary health care are a priority in modern medical systems. These topics generate significant political and public policy attention, particularly in the United States where healthcare is regarded as excessively costly but population health metrics lag similar nations. Health spending varies by country, which results in differences in access to care and access to medicines. Health care rationing varies by country. Most developed countries provide health care to all citizens, with a few exceptions such as the United States where restrictions on health insurance coverage may limit affordability.
The most intense 'peak' is reached within a minute or so and lasts for 1–5 minutes, followed by a gradual tapering off. At 5–10 minutes, less intense yet still noticeable effects typically persist, giving way to a returning sense of the everyday and familiar until back to baseline after about 15 to 20 minutes.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.